We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

120 hedge funds and large institutions have $2.1B invested in Zentalis Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 54 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

457% more call options, than puts

Call options by funds: $5.39M | Put options by funds: $969K

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

250% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 10

184% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 19

33% more capital invested

Capital invested by funds: $1.58B → $2.1B (+$527M)

26% more funds holding

Funds holding: 95 → 120 (+25)

8.44% more ownership

Funds ownership: 88.52% → 96.96% (+8.4%)

Holders
120
Holders Change
+25
Holders Change %
+26.32%
% of All Funds
2.09%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.07%
New
35
Increased
54
Reduced
19
Closed
10
Calls
$5.39M
Puts
$969K
Net Calls
+$4.43M
Net Calls Change
+$4.43M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$117M
2
APM
Avidity Partners Management
Texas
+$48M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$27.1M
4
Wells Fargo
Wells Fargo
California
+$27M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$22.3M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$96.2M
2
EAM
Eventide Asset Management
Massachusetts
-$22M
3
Franklin Resources
Franklin Resources
California
-$14.2M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$8.81M
5
SFM
Sphera Funds Management
Israel
-$7.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAA
26
Affinity Asset Advisors
New York
$7.58M +$3.48M +64,918 +84%
N
27
Nuveen
North Carolina
$7.27M +$1.06M +19,699 +17%
Two Sigma Investments
28
Two Sigma Investments
New York
$6.86M +$6.9M +128,871 New
Axa
29
Axa
France
$6.75M -$1.99M -37,067 -23%
IHAM
30
Integral Health Asset Management
New York
$6.65M +$4.55M +85,000 +213%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$5.05M +$270K +5,047 +6%
PVI
32
Pura Vida Investments
New York
$4.84M +$1.84M +34,293 +60%
Wellington Management Group
33
Wellington Management Group
Massachusetts
$4.69M +$4.73M +88,230 New
Goldman Sachs
34
Goldman Sachs
New York
$4.48M +$1.74M +32,480 +63%
TD Asset Management
35
TD Asset Management
Ontario, Canada
$4.36M +$2.83M +52,751 +181%
Bank of America
36
Bank of America
North Carolina
$4.35M -$467K -8,715 -10%
Citigroup
37
Citigroup
New York
$4.07M -$311K -5,807 -7%
Morgan Stanley
38
Morgan Stanley
New York
$3.64M +$825K +15,413 +29%
Ensign Peak Advisors
39
Ensign Peak Advisors
Utah
$3.44M +$3.01M +56,280 +678%
GI
40
GAMCO Investors
Connecticut
$3.34M – – –
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
$3M +$1.84M +34,283 +155%
Two Sigma Advisers
42
Two Sigma Advisers
New York
$2.9M +$937K +17,500 +47%
CCM
43
CAAS Capital Management
New York
$2.66M +$2.68M +50,000 New
Russell Investments Group
44
Russell Investments Group
United Kingdom
$2.47M +$1.24M +23,187 +99%
Rafferty Asset Management
45
Rafferty Asset Management
New York
$2.47M -$1.02M -19,078 -29%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$2.44M +$133K +2,488 +6%
MIM
47
Monashee Investment Management
Massachusetts
$2.39M +$2.41M +44,905 New
Swiss National Bank
48
Swiss National Bank
Switzerland
$2.38M +$161K +3,000 +7%
PCM
49
Pentwater Capital Management
Florida
$2.13M -$268K -5,000 -11%
Norges Bank
50
Norges Bank
Norway
$2.12M +$588K +10,980 +38%
1
2
3 4 5

ZNTL Hedge Fund Activity: Q2 2021 in Review

120 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q2 2021, worth a combined $2.1B — up 33% from $1.58B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ZNTL positions and 10 closed out — a net gain of 25 holders — while 54 added to existing stakes and 19 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $117M. The largest seller was Redmile Group, cutting an estimated $96.2M.

  • 120 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q2 2021, up from 95 in Q1 2021.
  • Funds reported $2.1B of Zentalis Pharmaceuticals stock for Q2 2021, up 33% quarter-over-quarter.
  • 35 funds opened new Zentalis Pharmaceuticals positions in Q2 2021 and 10 closed out, a net change of +25 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q2 2021 was T. Rowe Price Associates, an estimated $117M added.
  • The largest Zentalis Pharmaceuticals seller in Q2 2021 was Redmile Group, an estimated $96.2M sold.

Based on aggregated 13F filings for Q2 2021.